Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2025-05-28 Audit Report / Informat…
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Sprawozdanie finansowe 2024
Audit Report / Information Classification · 1% confidence The document text is titled "SPRAWOZDANIE FINANSOWE RYVU THERAPEUTICS S.A." (Financial Statement of RYVU THERAPEUTICS S.A.) and contains detailed sections such as 'Sprawozdanie z całkowitych dochodów' (Statement of Comprehensive Income), 'Sprawozdanie z sytuacji finansowej' (Statement of Financial Position/Balance Sheet), and 'Sprawozdanie ze zmian w kapitale własnym' (Statement of Changes in Equity), along with an extensive index of explanatory notes. The reporting period is clearly stated as the year ended December 31, 2024. This structure and content definitively classify it as a comprehensive annual financial report prepared according to IFRS (Międzynarodowymi Standardami Sprawozdawczości Finansowej). Although the document is in Polish, the content matches the definition of an Annual Report (10-K), which covers full yearly financial performance. Given the comprehensive nature and the full-year reporting period, 10-K is the most appropriate classification, even if it is a non-US filing, as it serves the function of the annual report. FY 2024
2025-05-28 Polish
Ogłoszenie ZWZ ENG
AGM Information Classification · 1% confidence The document explicitly states in the main heading: "Announcement of Annual General Meeting convened for June 26th, 2025." It details the agenda, procedures for attending, voting rights, and proxy rules, which are all characteristic elements of a notice for a General Meeting. This directly corresponds to the definition of AGM Information (AGM-R). It is not a full Annual Report (10-K), an Earnings Release (ER), or a proxy statement (PSI), but rather the formal notice convening the meeting itself.
2025-05-28 English
Ogłoszenie ZWZ PL
AGM Information Classification · 1% confidence The document is titled "Ogłoszenie o Zwyczajnym Walnym Zgromadzeniu zwołanym na dzień 26 czerwca 2025 r." which translates to "Announcement of the Annual General Meeting convened for June 26, 2025." The text details the agenda (Porządek obrad), procedures for participation, voting rights, and the record date for the meeting. This content is characteristic of a formal notice calling for a general shareholders' meeting. The closest matching category is AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although this is the *notice* of the meeting, it directly pertains to the AGM event itself, making AGM-R the most appropriate classification over a general regulatory filing (RNS) or a proxy statement (PSI), as it is the primary announcement of the meeting's details.
2025-05-28 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia Ryvu Therapeutics S.A / Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A. - Content (EN)
AGM Information Classification · 1% confidence The document explicitly states it is a 'Report Content Convening the Ordinary General Shareholders Meeting' and details the agenda for the 'Annual General Meeting of Shareholders' scheduled for June 26th, 2025. This content, which includes the notice and agenda for the AGM, aligns directly with the definition of AGM Information. Although it is a notice, the content is the core material for the meeting itself, making AGM-R the most precise fit over a general RPA or RNS.
2025-05-28 English
Zwołanie Zwyczajnego Walnego Zgromadzenia Ryvu Therapeutics S.A / Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A. - Content (PL)
AGM Information Classification · 1% confidence The document is a formal notice issued by the Management Board ('Zarząd') of Ryvu Therapeutics S.A. announcing the convening of the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie') scheduled for June 26, 2025. The text details the agenda ('Porządek obrad'), which includes reviewing the 2024 financial report, management report, and voting on resolutions, including discharge ('absolutorium') for board members. This content directly relates to the preparation and announcement of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2025-05-28 Polish
Report of the Manegement Board Q1 2025 EN
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Ryvu Therapeutics S.A. Q1 2025 Report' and contains comprehensive financial statements, including a statement of financial position, statement of comprehensive income, and management board commentary for the first quarter of 2025. It adheres to IAS 34 standards for interim reporting. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2025
2025-05-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.